ArticleHead and neck pathology2026
Characterization of CD8 + and CD68 + Microenvironment and PDL1 Expression in HPV-related Multiphenotypic Sinonasal Carcinoma.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterize the expression of CD8 + T cells, CD68 + macrophages, and PDL1 in HPV-related multiphenotypic sinonasal carcinoma (HMSC) and evaluate their correlations with clinical outcomes. MATERIALS AND
methodsThis retrospective cross-sectional study analyzed 27 HMSC cases. Clinical and histopathological data were obtained from medical records. Immunohistochemical expression of CD8 and CD68 was assessed quantitatively and qualitatively in stromal and intratumoral compartments. PDL1 expression was evaluated using the Combined Positive Score (CPS). HPV genotyping was performed using the Anyplex II HPV28 assay. Statistical analyses included descriptive statistics, Fisher's exact test, Chi-square test, Spearman's correlation, Student's t-test, Mann-Whitney U test, Kaplan-Meier survival analysis with log-rank test, and Cox proportional hazards models.
resultsThe cohort included 15 (55.6%) males and 12 (44.4%) females, with a mean age of 59.5 years. Most patients presented without recurrence (n = 17, 63.0%), lymph node metastasis (n = 22, 81.5%), or distant metastasis (n = 23, 85.2%). HPV-33 was the predominant genotype, detected in 17 cases (63.0%). PDL1 positivity was observed in 12 tumors (44.4%) and correlated with increased CD8 + infiltration (ρ = 0.602, p < 0.01). Higher densities of CD8 + T cells and CD68 + macrophages were associated with reduced recurrence risk. Older age correlated with higher Ki67 index (ρ = 0.452, p < 0.05), lower PDL1 expression (ρ=-0.436, p < 0.05), and increased recurrence. Lymph node and distant metastases were associated with poorer disease-specific survival (p = 0.020 and p = 0.010, respectively).
conclusionsThe immune microenvironment, characterized by CD8 + and CD68 + cell density and PDL1 expression, together with patient age, appears to influence clinical outcomes in HMSC. These findings suggest that a subset of HMSC patients, particularly those with an inflamed tumor microenvironment, may be candidates for PDL1-targeted immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.